摘要
目的研究多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌的效果及对糖类多肽抗原125(CA125)、人附睾分泌蛋白4(HE4)水平的影响。方法队列研究。抽取2017年1月至2021年12月漯河医学高等专科学校第二附属医院收治的晚期卵巢癌患者76例,按随机数字表法分为单一组和联合组,每组38例。单一组采用多西他赛治疗,联合组在单一组基础上采用洛铂腹腔灌注治疗。比较两组治疗效果及不良反应发生率。比较两组治疗后肿瘤标志物(CA125、HE4)水平、卡氏功能状态评分表(KPS)评分。结果联合组总有效率(84.21%,32/38)高于单一组(60.53%,23/38),P<0.05。治疗后,联合组CA125、HE4水平低于单一组(P<0.05),KPS评分高于单一组(P<0.05)。联合组恶心呕吐(13.16%,5/38)、腹痛(7.89%,3/38)、白细胞减少(5.26%,2/38)、腹泻(7.89%,3/38)发生率与单一组(7.89%,3/38;10.53%,4/38;10.53%,4/38;5.26%,2/38)比较差异未见统计学意义(P>0.05)。结论多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌效果显著,能降低肿瘤标志物水平,改善患者健康状态,且不会增加不良反应发生率。
Objective To investigate the effect of docetaxel combined with intraperitoneal infusion with lobaplatin in the treatment of advanced ovarian cancer,and its influence on levels of carbohydrate peptide antigen 125(CA125)and human epididymal secretion protein 4(HE4).Methods A total of 76 patients with advanced ovarian cancer treated in the Second Affiliated Hospital of Luohe Medical College from January 2017 to December 2021 were selected for the cohort study.And they were divided into a single group and a combined group according to random number table method,with 38 cases in each group.The single group was treated with docetaxel,and the combined group was treated by intraperitoneal infusion with lobaplatin based on the treatment of the single group.The therapeutic effects and incidence of adverse reactions were compared between the two groups.The preoperative and postoperative levels of tumor markers(CA125,HE4)and Karnofsky performance status(KPS)scores were compared between the two groups.Results The total effective rate of the combined group(84.21%,32/38)was higher than that of the single group(60.53%,23/38),P<0.05.After treatment,the levels of CA125 and HE4 in the combined group were lower than those in the single group(P<0.05),and the KPS score in the combined group was higher than that in the single group(P<0.05).The incidence of nausea and vomiting(13.16%,5/38),abdominal pain(7.89%,3/38),leucopenia(5.26%,2/38),and diarrhea(7.89%,3/38)in the combined group had no significantly difference in comparison with the single group(7.89%,3/38;10.53%,4/38;10.53%,4/38;5.26%,2/38),P>0.05.Conclusions Docetaxel combined with intraperitoneal infusion with lobaplatin is effective in the treatment of advanced ovarian cancer,which can reduce the levels of tumor markers,and improve the health status of patients,without increasing the incidence of adverse reactions.
作者
曹慧芳
周希山
于苗子
Cao Huifang;Zhou Xishan;Yu Miaozi(Department of Internal Medicine IV,the Second Affiliated Hospital of Luohe Medical College,Luohe 462300,China;Department of Oncology,the Second Affiliated Hospital of Luohe Medical College,Luohe 462300,China;Department of Oncology Surgery,the Second Affiliated Hospital of Luohe Medical College,Luohe 462300,China)
出处
《中国实用医刊》
2024年第11期82-85,共4页
Chinese Journal of Practical Medicine
关键词
卵巢癌
晚期
多西他赛
洛铂
腹腔灌注
Ovarian neoplasms
Advanced
Docetaxel
Lobaplatin
Intraperitoneal infusion
